This most up-to-date twist from the Lykos Therapeutics saga threatens a major overhaul of the organization’s approach and course, with Musk ally and billionaire Trader Antonio Gracias showing up to want to take the company back toward its nonprofit drug growth roots and a more Doblinite philosophy.The food items allergy software was filed because